| __timestamp | Agios Pharmaceuticals, Inc. | Xenon Pharmaceuticals Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 19120000 | 5496000 |
| Thursday, January 1, 2015 | 35992000 | 9786000 |
| Friday, January 1, 2016 | 50714000 | 6792000 |
| Sunday, January 1, 2017 | 71124000 | 7313000 |
| Monday, January 1, 2018 | 114145000 | 8382000 |
| Tuesday, January 1, 2019 | 132034000 | 10803000 |
| Wednesday, January 1, 2020 | 149070000 | 12944000 |
| Friday, January 1, 2021 | 121445000 | 21967000 |
| Saturday, January 1, 2022 | 121673000 | 32810000 |
| Sunday, January 1, 2023 | 119903000 | 46542000 |
| Monday, January 1, 2024 | 156784000 |
Unleashing insights
In the competitive world of biotechnology, effective cost management is crucial. Over the past decade, Agios Pharmaceuticals, Inc. and Xenon Pharmaceuticals Inc. have demonstrated contrasting strategies in managing their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Agios Pharmaceuticals saw a steady increase in SG&A expenses, peaking in 2020 with a 680% rise from 2014 levels. This reflects their aggressive expansion and investment in administrative capabilities. In contrast, Xenon Pharmaceuticals maintained a more conservative approach, with a 747% increase over the same period, but starting from a much lower base. By 2023, Xenon's SG&A expenses were approximately 39% of Agios's, highlighting their leaner operational model. These trends underscore the diverse strategies within the biotech sector, where balancing growth and cost efficiency remains a pivotal challenge.
Operational Costs Compared: SG&A Analysis of Zoetis Inc. and Agios Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Xenon Pharmaceuticals Inc.
Neurocrine Biosciences, Inc. vs Agios Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Insmed Incorporated or Xenon Pharmaceuticals Inc.
Cost Management Insights: SG&A Expenses for Dr. Reddy's Laboratories Limited and Xenon Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and Agios Pharmaceuticals, Inc.
Axsome Therapeutics, Inc. and Xenon Pharmaceuticals Inc.: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? TG Therapeutics, Inc. or Agios Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Verona Pharma plc and Xenon Pharmaceuticals Inc.
Selling, General, and Administrative Costs: Amneal Pharmaceuticals, Inc. vs Xenon Pharmaceuticals Inc.
Cost Management Insights: SG&A Expenses for PTC Therapeutics, Inc. and Agios Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Catalyst Pharmaceuticals, Inc. and Agios Pharmaceuticals, Inc.